Page last updated: 2024-08-05 11:02:32

bromobenzenes

A member of the class of benzenes that is benzene substituted by at least one bromo group.

ChEBI ID: 37149

Members (13)

MemberDefinitionRole
azd 6244A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor.selumetinib
binimetinibA member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib.binimetinib
brodimoprimAn aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group.brodimoprim
bromobenzeneThe simplest member of the class of bromobenzenes, that is benzene in which a single hydrogen has been substituted by a bromine. A liquid at room temperature (m.p. -30degreeC; b.p.760 156degreeC), it is used as a solvent, particularly for large-scale crystallisations, and for the introduction of phenyl groups in organic synthesis.bromobenzene
cl 387785A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide
l-798106An N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of o-naphthalen-2-ylcinnamic acid with the sulfonamide group of 5-bromo-2-methoxybenzenesulfonamide. It is a selective antagonist for the prostanoid receptor EP3, a prostaglandin receptor for prostaglandin E2 (PGE2).L-798106
leptophosAn organic phosphonate that is phenylphosphonothioic O,O-acid in which the hydroxy groups are substituted by methoxy and 4-bromo-2,5-dichlorophenoxy groups.O-(4-bromo-2,5-dichlorophenyl) O-methyl phenylphosphonothioate
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamideA member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
pd 153035A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.PD-153035
pd 158780A pyridopyrimidine that is pyrido[3,4-d]pyrimidine-4,6-diamine in which the amino groups at positions 4 and 6 are substituted by a m-bromophenyl group and a methyl group, respectively. It is a potent, cell-permeable, reversible ATP-competitive inhibitor of EGFR tyrosine kinase activity [IC50 values of 0.008, 49 and 52 nM for EGFR, ErbB2 (HER2) and Erb4 (HER4)]. It does not inhibit FGF or PDGF-mediated tyrosine phosphorylation. Induces G1 cell cycle arrest in MCF10A cells and is antiproliferative in A431 human epidermal carcinoma cells.PD158780
pd168393A member of the class of quinazolines carrying bromoanilino and acrylamido substituents at positions 4 and 6 respectively.PD 168393
ro 48-8071An aromatic ketone that is 2-fluoro-4'-bromobenzophenone in which the hydrogen at position 4 (meta to the fluoro group) is replaced by a 6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy group. An inhibitor of lanosterol synthase.Ro 48-8071
sr9243A sulfonamide resulting from the formal condensation of the sulfonic acid group of mesitylene-2-sulphonic acid with the amino group of 2-(m-bromophenyl)ethylamine in which the nitrogen is substituted by a 4-[m-(methylsulfonyl)phenyl]benzyl group.SR9243

Research

Studies (1,421)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-1990187 (13.16)18.7374
1990's161 (11.33)18.2507
2000's273 (19.21)29.6817
2010's616 (43.35)24.3611
2020's184 (12.95)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials131 (8.62%)5.53%
Reviews73 (4.80%)6.00%
Case Studies42 (2.76%)4.05%
Observational3 (0.20%)0.25%
Other1,271 (83.62%)84.16%